Cencora Leaders Share Insights at Asembia ASX26, Affirming Commitment to Accelerating Access to Innovative Specialty Medicines

At Asembia ASX26, the following Cencora leaders shared insights with Pharmaceutical Executive, Pharmaceutical Commerce, Drug Topics and AJMC:

Jessica Lovett, VP, Clinical Strategy & Innovation, Innomar

Managing uncertainty with strategic planning, adaptable market approaches, and reliable, data-driven collaborations to safeguard supply and ensure patient access – Access article

Patient support programs and registry data serve as real-world evidence (RWE) to enhance access, guide decisions, and maximize patient outcomes throughout the specialty product lifecycle – Access article

Establishing strong manufacturer partnerships by addressing stakeholder needs, leveraging data insights, promoting cross-functional teamwork and employing adaptable strategies for market and supply chain uncertainties – Access article

The need for disciplined, market‑specific planning, rather than relying on one‑size‑fits‑all global strategies when navigating global political and regulatory uncertainty – Access article

Defining forces shaping pharma over the next few years and what’s needed for leaders to stay flexible and disciplined in how they plan and respond – Access article

Tommy Bramley, SVP, Global Consulting Services, Cencora

Evolving U.S. and global regulations on real-world evidence are prompting pharma to use rigorous methods and quality data in global launch strategies – Access article

RWE’s greatest value in specialty pharma: informing payer access, guiding clinician decisions beyond trials and proving real-world outcomes, particularly for high-cost, small-population therapies where traditional data are scarce – Access article

Predictions on pharma’s future—shaped by increasing complexity, including specialty and cell-and-gene therapies, evolving evidence requirements and access expectations – Access article

Ryan Telford, VP, of Health System Pharmacy Portfolio Strategy, Cencora

Technology and AI’s role as “complexity‑cutters” in specialty care to streamline access, affordability and adherence while freeing pharmacists from administrative tasks so they can stay at the center of care – Access article

How pharmacists can adapt to rapid change by treating agility as a core capability—using incremental automation to offload repetitive tasks, embracing innovation at every scale and stepping into a central, connective role across the patient journey for complex and specialty therapies – Access article

Combining automation and technology with strong partnerships and focus on sustainability to drive real gains in pharmacy efficiency and access—freeing pharmacists to practice at the top of their license while helping ensure emerging therapies like cell and gene treatments can reach patients at scale in a financially viable way – Access article